Prospective observational study on third-line treatments in neuroendocrine carcinoma – Data from the phase II SENECA trial

#3865

Introduction: Neuroendocrine Carcinoma (NEC) are very rare and characterized by a poor prognosis. Therapeutic opportunities for metastatic disease beyond the first line are very limited.

Aim(s): Our aim is to evaluate the impact on the outcome of 3rd-line treatments in mNEC patients (pts).

Materials and methods: We prospectively collect data on 3rd-line therapies on 47 of 56 mNEC pts enrolled in the phase II multicentric SENECA trial. G3-G4 toxicities were also collected. All pts signed an informed consent.

Conference:

Presenting Author: Liverani C

Authors: Bongiovanni A, Liverani C, Morbini S, Pusceddu S, Gelso F,

Keywords: neuroendocrine carcinoma, FOLFIRI, CAPTEM, third line, chemotherapy,